The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres
Abstract
BACKGROUND: The objective of the current study was to determine the safety and efficacy of Yttrium‐90 (Y90) microsphere treatment in patients with liver‐dominant colorectal metastases. METHODS: Seventy‐two patients with unresectable hepatic colorectal metastases were treated at a targeted absorbed dose of 120 Gray (Gy). Safety and toxicity were assessed using version 3 of the National Cancer Institute Common Terminology Criteria. Response was assessed by anatomic imaging and positron emission tomography (PET). Survival from the diagnosis of hepatic metastases and first treatment were estimated using the Kaplan‐Meier method. Substratification analyses were performed. RESULTS: The median dose delivered was 118 Gy. Treatment‐related toxicities included fatigue (61%), nausea (21%), and abdominal pain (25%). Grade 3 and 4 bilirubin toxicities were observed in 9 of 72 patients (12.6%). The tumor response rate was 40.3%. The median time to hepatic progression was 15.4 months, and the median response duration was 15 months. The PET response rate was 77%. Overall survival from the first Y90 treatment was 14.5 months. Tumor replacement (≤25% vs >25%) was associated with significantly greater median survival (18.7 months vs 5.2 months). The presence of extrahepatic disease was associated negatively with overall survival (7.9 months vs 21 months). Overall survival from the date of initial hepatic metastases was 34.6 months. A subset analysis of patients who had an Eastern Cooperative Oncology Group performance status of 0 demonstrated a median survival of 42.8 months and 23.5 months from the time of hepatic metastases and Y90 treatment, respectively. CONCLUSIONS: Y90 liver therapy appears to provide sustained disease stabilization with acceptable toxicity. Asymptomatic patients with preserved liver function at the time of Y90 appeared to benefit most from treatment. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 1×
“6%), FUDR (44%), sequential chemotherapy (the Medical Research Council Fluorouracil, Oxaliplatin, and CPT11 [irinotecan] Use and Sequencing or FOCUS trial, 11%-23%; the Capecitabine, Irinotecan, and Oxaliplatin in Advanced Colorectal Cancer of CAIRO trial, 4%-12%), and previous cohorts of Y90 (35%).(19,21,26-29) Simil…”
Result
Cited by
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y.-J., Choti, M. A., Cooper, H. S., Covey, A., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0057 · Cited by 439
Self-citationSolbiati, L., Ahmed, M., Cova, L., Ierace, T., Brioschi, M., & Goldberg, S. N. (2012) · Radiology · doi:10.1148/radiol.12111851 · Cited by 366
Metadata
- Authors
- Mulcahy, M. F., Lewandowski, R. J., Ibrahim, S. M., Sato, K. T., Ryu, R. K., Atassi, B., Newman, S., Talamonti, M., Omary, R. A., Benson, A., & Salem, R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-04-20
- Volume
- 115
- Issue
- 9
- Pages
- 1849-1858
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2043559301
- Cited by
- 180
- References
- 2
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres. https://app.cochat.ai/papers/10.1002/cncr.24224
- The paper
- Mulcahy, M. F., Lewandowski, R. J., Ibrahim, S. M., Sato, K. T., Ryu, R. K., Atassi, B., Newman, S., Talamonti, M., Omary, R. A., Benson, A., & Salem, R. (2009). Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres. Cancer. https://doi.org/10.1002/cncr.24224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.